DK2712618T3 - Målrettet administration af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller ved hjælp af intakte dræbte bakterieceller - Google Patents

Målrettet administration af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller ved hjælp af intakte dræbte bakterieceller Download PDF

Info

Publication number
DK2712618T3
DK2712618T3 DK13191266.9T DK13191266T DK2712618T3 DK 2712618 T3 DK2712618 T3 DK 2712618T3 DK 13191266 T DK13191266 T DK 13191266T DK 2712618 T3 DK2712618 T3 DK 2712618T3
Authority
DK
Denmark
Prior art keywords
cell
cells
killed bacterial
nucleic acid
vol
Prior art date
Application number
DK13191266.9T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Application granted granted Critical
Publication of DK2712618T3 publication Critical patent/DK2712618T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (17)

  1. Målrettet administration af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller ved hjælp af intakte dræbte bakterieceller
    1. Præparat til anvendelse ved behandling af en sygdom, hvor præparatet omfatter: (a) en flerhed af intakte dræbte bakterieceller, idet hver dræbt bakteriecelle i flerheden besidder en intakt cellevæg og/eller cellemembran, indeholder genetisk materiale, som er endogent for bakteriearten, og omfatter (i) en terapeutisk nukleinsyre, der koder for et produkt, såsom et peptid, polypeptid eller protein, hvis produktion er ønsket i en målcelle, (ii) et lægemiddel, der er et fysiologisk eller farmaceutisk aktivt stof, som frembringer en ønsket lokal eller systemisk virkning hos pattedyr og mennesker, eller (iii) et funktionelt nukleinsyremolekyle, der efter indføring i en værtscelle specifikt interfererer med ekspression af et protein, (b) en farmaceutisk acceptabel bærer dertil og (c) en bispecifik ligand, der er bundet til hver intakt dræbt bakteriecelle.
  2. 2. Præparat til anvendelse ved behandling af en sygdom, hvor præparatet omfatter: (a) en flerhed af intakte dræbte bakterieceller, idet hver dræbt bakteriecelle i flerheden besidderen intakt cellevæg og/eller cellemembran, indeholder genetisk materiale, som er endogent for bakteriearten, og omfatter (i) en terapeutisk nukleinsyre, der koder for et produkt, såsom et peptid, polypeptid eller protein, hvis produktion er ønsket i en målcelle, (ii) et lægemiddel, der er et fysiologisk eller farmaceutisk aktivt stof, som frembringer en ønsket lokal eller systemisk virkning hos pattedyr og mennesker, eller (iii) et funktionelt nukleinsyremolekyle, der efter indføring i en værtscelle specifikt interfererer med ekspression af et protein, (b) en farmaceutisk acceptabel bærer dertil og (c) en bispecifik ligand, der er bundet til hver intakt dræbt bakteriecelle, og hvor anvendelsen omfatter administration af præparatet til en celle, et væv eller et organ.
  3. 3. Præparat til anvendelse ved behandling af en sygdom ved administration af en payload til en målcelle in vivo, hvor præparatet omfatter: (a) en flerhed af intakte dræbte bakterieceller, idet hver dræbt bakteriecelle i flerheden besidder en intakt cellevæg og/eller cellemembran, indeholder genetisk materiale, som er endogent for bakteriearten, og omfatter en payload, der er valgt blandt (i) en terapeutisk nukleinsyre, der koder for et produkt, såsom et peptid, polypeptid eller protein, hvis produktion er ønsket i en målcelle, (ii) et lægemiddel, der er et fysiologisk eller farmaceutisk aktivt stof, som frembringer en ønsket lokal eller systemisk virkning hos pattedyr og mennesker, og (iii) et funktionelt nukleinsyremolekyle, der efter indføring i en værtscelle specifikt interfererer med ekspression af et protein, (b) en farmaceutisk acceptabel bærer dertil og (c) en bispecifik ligand, der er bundet til hver intakt dræbt bakteriecelle, og hvor anvendelsen omfatter, at målcellen bringes i kontakt med præparatet, hvorefter målcellen opsluger en intakt dræbt bakteriecelle i præparatet, og den intakte dræbte bakteriecelle efter opslugningen frigiver den pågældende payload til målcellen.
  4. 4. Præparat til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor de dræbte bakterieceller indeholder et lægemiddel.
  5. 5. Præparat til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor de dræbte bakterieceller indeholder funktionel nukleinsyre.
  6. 6. Præparat til anvendelse ifølge krav 5, hvor den funktionelle nukleinsyre er plasmidfri.
  7. 7. Præparat til anvendelse ifølge krav 5, hvor den funktionelle nukleinsyre er målrettet mod transkriptet af et protein, som fremmer lægemiddelresistens, inhiberer apoptose eller fremmer en neoplastisk fænotype.
  8. 8. Præparat til anvendelse ifølge krav 7, hvor den funktionelle nukleinsyre er et siRNA, shRNA eller miRNA, der er målrettet mod transkriptet af et protein, som fremmer lægemiddelresistens.
  9. 9. Præparat til anvendelse ifølge krav 7, hvor den funktionelle nukleinsyre er målrettet mod transkriptet af P-glycoprotein, MDR-2 eller MDR-3.
  10. 10. Præparat til anvendelse ifølge krav 7, hvor den funktionelle nukleinsyre er målrettet mod transkriptet af MRP2, BCR-ABL, STI-571 Resistance-associeret protein, Lung Resistance-relateret protein, cyclooxygenase-2, cellekernefaktor-kappa, XRCC1, ERCC1, GSTP1, mutant β-tubulin eller en vækstfaktor.
  11. 11. Præparat til anvendelse ifølge krav 7, hvor den funktionelle nukleinsyre er målrettet mod transkriptet af et protein, der inhiberer apoptose.
  12. 12. Præparat til anvendelse ifølge krav 7, hvor den funktionelle nukleinsyre er målrettet mod et transkript af et protein, der fremmer en neoplastisk fænotype.
  13. 13. Præparat til anvendelse ifølge krav 7, hvilket præparat yderligere omfatter et lægemiddel.
  14. 14. Præparat til anvendelse ifølge krav 13, hvor lægemidlet er emballeret i en dræbt bakteriecelle.
  15. 15. Præparat til anvendelse ifølge et hvilket som helst af kravene 1-14, hvor den bispecifikke ligand omfatter et antistof eller antistoffragment.
  16. 16. Præparat til anvendelse ifølge et hvilket som helst af kravene 1-15, hvor den bispecifikke ligand omfatter en første arm, der bærer specificitet for en bakteriecelle-overfladestruktur, og en anden arm, der bærer specificitet for en ikke-fagocytisk pattedyrcelle-overfladereceptor.
  17. 17. Præparat ifølge krav 2, hvor den terapeutiske nukleinsyre efter indføring i en værtscelle påvirker immunresponser associeret med allergenet eller den infektiøse agens, og hvor sygdommen er en allergenmedieret eller infektiøs agens-medieret inflammatorisk lidelse.
DK13191266.9T 2006-06-23 2007-06-20 Målrettet administration af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller ved hjælp af intakte dræbte bakterieceller DK2712618T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81588306P 2006-06-23 2006-06-23
US90907807P 2007-03-30 2007-03-30
EP07825666.6A EP2040725B1 (en) 2006-06-23 2007-06-20 Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Publications (1)

Publication Number Publication Date
DK2712618T3 true DK2712618T3 (da) 2017-01-30

Family

ID=38981849

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13191266.9T DK2712618T3 (da) 2006-06-23 2007-06-20 Målrettet administration af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller ved hjælp af intakte dræbte bakterieceller
DK07825666.6T DK2040725T3 (da) 2006-06-23 2007-06-20 Målrettet afgivelse af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller via intakte dræbte bakterieceller

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07825666.6T DK2040725T3 (da) 2006-06-23 2007-06-20 Målrettet afgivelse af lægemidler, terapeutiske nukleinsyrer og funktionelle nukleinsyrer til pattedyrceller via intakte dræbte bakterieceller

Country Status (15)

Country Link
US (4) US9878043B2 (da)
EP (2) EP2040725B1 (da)
CN (1) CN101505768B (da)
AU (1) AU2007278899B2 (da)
CA (1) CA2658058C (da)
CY (1) CY1118437T1 (da)
DK (2) DK2712618T3 (da)
ES (2) ES2610703T3 (da)
HK (1) HK1129845A1 (da)
HU (1) HUE033007T2 (da)
LT (1) LT2712618T (da)
PL (2) PL2040725T3 (da)
PT (2) PT2040725E (da)
SI (2) SI2040725T1 (da)
WO (1) WO2008012695A2 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380612T3 (es) * 2001-10-15 2012-05-16 Engeneic Molecular Delivery Pty Ltd. Minicélulas intactas como vectores para transferencia de ADN y terapia génica in vitro e in vivo
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
JP4332558B2 (ja) 2003-12-09 2009-09-16 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来のインタクトなミニ細胞を介した非食作用性哺乳動物細胞への標的化遺伝子送達
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
ME02251B (me) 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija
US8691963B2 (en) 2004-08-26 2014-04-08 Engeneic Molecular Delivery Pty. Ltd. Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP1799825B1 (en) 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
KR100967868B1 (ko) 2004-12-17 2010-07-05 베쓰 이스라엘 디코니스 메디칼 센터 박테리아 매개 유전자 침묵을 위한 조성물 및 이것을이용하는 방법
JP4940729B2 (ja) † 2006-03-31 2012-05-30 株式会社ジェイテクト 工作物の研削方法及び研削装置
PT2040725E (pt) * 2006-06-23 2014-04-24 Engeneic Molecular Delivery Pty Ltd Distribuição dirigida de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamífero através de células bacterianas mortas intactas
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
US20080311081A1 (en) * 2007-06-15 2008-12-18 Johannes Fruehauf Bacteria mediated gene silencing
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US8450106B2 (en) 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
CA2729545C (en) * 2008-06-25 2019-07-09 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
WO2011035018A2 (en) * 2009-09-18 2011-03-24 Fate Therapeutics, Inc. Suicide ready cells
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
SG10201601349XA (en) * 2011-12-13 2016-03-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
CA2872930A1 (en) * 2012-05-09 2013-11-14 Gradalis, Inc. Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
GB201219024D0 (en) * 2012-10-23 2012-12-05 Syntaxin Ltd Assay
EA032740B1 (ru) 2013-10-04 2019-07-31 Энджинеик Молекьюлар Деливери Пти Лтд Способ лечения опухоли у индивидуума и набор для осуществления способа
EP3077050B1 (en) 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
JP2017514908A (ja) 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
WO2016037071A2 (en) 2014-09-05 2016-03-10 Rxi Pharmaceuticals Corporation Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP7029957B2 (ja) 2014-10-03 2022-03-04 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド インタクトな細菌由来のベシクルへの低分子化合物の充填の向上
WO2017007813A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
TWI724099B (zh) * 2016-01-28 2021-04-11 日商康貝股份有限公司 用於改善或預防疱疹病毒感染症之組合物
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017201193A1 (en) * 2016-05-17 2017-11-23 Cornell University Compositions and methods for the expression of eukaryotic oligosaccharides on bacterial outer membrane vesicles
JP7213798B2 (ja) 2016-10-06 2023-01-27 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11202100507PA (en) 2018-07-23 2021-02-25 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
CN113507936A (zh) * 2019-01-04 2021-10-15 安吉尼科分子传输公司 用于治疗赘生性疾病的包封的糖脂抗原
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4055167A2 (en) 2019-11-08 2022-09-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
EP4085136A1 (en) 2019-12-31 2022-11-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
EP4381070A2 (en) 2021-08-04 2024-06-12 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6177083B1 (en) 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
BR9407433A (pt) * 1993-09-08 1996-04-09 Merck Patent Gmbh Reagente e teste de célula
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
AU6762498A (en) 1997-03-19 1998-10-12 Zymogenetics Inc. Secreted salivary zsig32 polypeptides
US20030004123A1 (en) 1997-06-26 2003-01-02 Boucher Richard C. Targeted gene transfer using G protein coupled receptors
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
AU781598B2 (en) * 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000067769A1 (en) 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
US7125679B2 (en) 2001-03-07 2006-10-24 Children's Medical Center Corporation Methods to screen peptide libraries using minicell display
PL366637A1 (en) * 2001-05-16 2005-02-07 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
ES2380612T3 (es) * 2001-10-15 2012-05-16 Engeneic Molecular Delivery Pty Ltd. Minicélulas intactas como vectores para transferencia de ADN y terapia génica in vitro e in vivo
EP2272946B9 (en) 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minicell compositions and methods
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
JP4332558B2 (ja) * 2003-12-09 2009-09-16 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来のインタクトなミニ細胞を介した非食作用性哺乳動物細胞への標的化遺伝子送達
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8691963B2 (en) 2004-08-26 2014-04-08 Engeneic Molecular Delivery Pty. Ltd. Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
KR100967868B1 (ko) * 2004-12-17 2010-07-05 베쓰 이스라엘 디코니스 메디칼 센터 박테리아 매개 유전자 침묵을 위한 조성물 및 이것을이용하는 방법
PT2040725E (pt) * 2006-06-23 2014-04-24 Engeneic Molecular Delivery Pty Ltd Distribuição dirigida de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamífero através de células bacterianas mortas intactas

Also Published As

Publication number Publication date
HUE033007T2 (en) 2017-11-28
US20110275585A1 (en) 2011-11-10
CY1118437T1 (el) 2017-06-28
US20180250413A1 (en) 2018-09-06
LT2712618T (lt) 2017-02-27
EP2040725A2 (en) 2009-04-01
AU2007278899A8 (en) 2009-03-12
EP2712618A1 (en) 2014-04-02
US20080038296A1 (en) 2008-02-14
ES2610703T3 (es) 2017-05-03
US20140155343A1 (en) 2014-06-05
PT2040725E (pt) 2014-04-24
HK1129845A1 (en) 2009-12-11
CN101505768A (zh) 2009-08-12
PL2712618T3 (pl) 2017-07-31
SI2040725T1 (sl) 2014-08-29
US8591862B2 (en) 2013-11-26
PT2712618T (pt) 2017-01-26
EP2712618B1 (en) 2016-10-19
PL2040725T3 (pl) 2014-08-29
US9878043B2 (en) 2018-01-30
ES2458498T3 (es) 2014-05-05
EP2040725A4 (en) 2011-06-22
AU2007278899A1 (en) 2008-01-31
WO2008012695A3 (en) 2008-04-24
US11357860B2 (en) 2022-06-14
DK2040725T3 (da) 2014-04-22
CA2658058A1 (en) 2008-01-31
AU2007278899A2 (en) 2009-02-19
CN101505768B (zh) 2013-11-06
WO2008012695A2 (en) 2008-01-31
AU2007278899B2 (en) 2012-09-06
US11147883B2 (en) 2021-10-19
EP2040725B1 (en) 2014-01-15
SI2712618T1 (sl) 2017-02-28
CA2658058C (en) 2016-08-23

Similar Documents

Publication Publication Date Title
US11357860B2 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US10426736B2 (en) Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
AU2015201118B2 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
AU2012261512B2 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
AU2017203234B2 (en) Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells